Modern aspects of bronchial asthma pathogenesis and treatment


DOI: https://dx.doi.org/10.18565/therapy.2019.6.163-165

Trophymov V.I.

I.P. Pavlov First St. Petersburg State medical University of the Ministry of Healthcare of Russia
The review presents modern conceptions about the pathogenesis of bronchial asthma and the actual methods of its treatment with a focus on the allergic form of the disease. Targeted drugs - monoclonal antibodies, which are proposed for the treatment of patients with moderate and severe asthma in cases where the disease cannot be controlled using traditional inhalation agents, are separately considered.
Keywords: allergic bronchial asthma, monoclonal antibodies, targeted therapy, bronchial asthma
Read entire article

Literature


  1. Nunes C., Pereira A.M., Morais-Almeida M. Asthma costs and social impact. Asthma Res.Pract. 2017; 3: 1.

  2. Chung K.F., Wenzel S.E. , Brozek J.L. et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur.Resp.J. 2014; 43: 343–73.

  3. Адо А.Д., Булатов П.К. Клинико-физиологические основы классификации бронхиальной астмы. Материалы к V межобластной научной конференции терапевтов «Этиология, патогенез, клиника и лечение заболеваний органов дыхания». Л., 1969; 258–265.

  4. Федосеев Г.Б., Коровина О.В., Тенигина Н.Г. Комплексная диагностика различных клинико-патогенетических вариантов бронхиальной астмы. Терапевтический архив. 1977; 6: 51–55.

  5. Sze E., Bhalle A., Nair P. Mechanisms and therapeutic strategies for Non-T2 asthma. Allergy. 2019 Jul 16. doi: 10.1111/all.13985.

  6. Галицкая М.А., Курбачева О.М. Современные представления о роли врожденного и приобретенного иммунитета при бронхиальной астме. Российский аллергологический журнал. 2018; 15(6): 7–17.

  7. Reddel H.K., FitzGerald J.M., Bateman E.D. et al. GINA 2019: a fundamental change in asthma management. Eur.Resp.J. 2019; 53: 1901046.

  8. Ortega M.G., Lui M.C., Pavord J.M. et al. Menolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014; 371: 1198–207.

  9. BleecKer E.R., FitzGerald J.M., Chanez P. et al. Efficacy and safety of Benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomized, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388: 2115–27.

  10. Castro M., Zangrilli J., Wechsler M.B. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts; results from two multicentre, parallel, doubleblind, randomized, placebo-controlled, phase 3 trials. Lancet Respir. Med. 2015; 3: 355–66.

  11. Rabe K.F., Nair P., Brusselle G. et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Eng J Med. doi: 10.1056/NEJ Mon 1804093.

  12. Corran J., Parnes J.R., Wang L. et al. Tazepelumab in Adults with uncontrolled Asthma with uncontrolled Asthma. N Eng J Med. 2017; 377(10): 936–46.


About the Autors

Vasily I. Trofimov, MD, professor, head of the Department of hospital therapy with a course of allergology and immunology named after acad. M.V. Chernorutsky with the clinic of I.P. Pavlov First St. Petersburg State medical University of the Ministry of Healthcare of Russia. Address: 197022, St. Petersburg, 6/8 Leo Tolstoy Str. Tel.: +7 (812) 338-67-46. E-mail: trofvi@mail.ru


Similar Articles

Back to Content

Бионика Медиа